GEORGE HUTTON to Treatment Outcome
This is a "connection" page, showing publications GEORGE HUTTON has written about Treatment Outcome.
Connection Strength
0.087
-
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015 Feb; 72(2):159-69.
Score: 0.029
-
Heart-shaped lesion secondary to neurosarcoidosis. Arch Neurol. 2008 Oct; 65(10):1388-9.
Score: 0.019
-
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
Score: 0.011
-
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
Score: 0.010
-
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017 Feb 28; 88(9):842-852.
Score: 0.008
-
Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009 Feb 10; 72(6):535-41.
Score: 0.005
-
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data. Mult Scler. 2008 Apr; 14(3):370-82.
Score: 0.004